SEC FORM 3

Please wait

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

PYOTT DAVID E I

(Last)

(First)

(Middle)

C/O TARSUS PHARMACEUTICALS

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE

92618

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/18/2026

3. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,991	I	By the David E.I. Pyott Trust

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	06/19/2032	Common Stock	7,000	$12.97	D
Stock Option (right to buy)	⁽²⁾	07/31/2033	Common Stock	2,500	$18.27	D
Stock Option (right to buy)	⁽³⁾	04/23/2034	Common Stock	2,500	$32.76	D
Stock Option (right to buy)	⁽⁴⁾	04/23/2035	Common Stock	2,128	$49.97	D
Restricted Stock Units	⁽⁵⁾	⁽⁵⁾	Common Stock	1,383	$0	D

Explanation of Responses:

1. Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan (the "Plan"). The option shares vested and became exercisable on April 24, 2023.

2. Option granted under the Plan. The option shares vested and became exercisable on August 1, 2024.

3. Option granted under the Plan. The option shares vested and became exercisable on April 24, 2025.

4. Option granted under the Plan. The option shares vest and become exercisable on April 24, 2026, subject to the Reporting Person's continuous service.

5. Restricted Stock Units ("RSUs") granted under the Plan. The RSUs vest on April 24, 2026, subject to the Reporting Person's continuous service.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Scott Sieckert, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.